Stem Cell Transplants for Early MS: Who Benefits Most?
Researchers are exploring HSCT as a rescue therapy in early-stage MS. But there's no consensus on best practices.
Stay updated with breaking news from Stem Cell Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers are exploring HSCT as a rescue therapy in early-stage MS. But there's no consensus on best practices.
The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.
At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.
Hematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed.
A chemoimmunotherapy and radiation combination without autologous stem cell transplant produced high response rates in children and young adults with low-risk relapsed/refractory Hodgkin lymphoma.